Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 1:18 PM
Ignite Modification Date:
2025-12-26 @ 1:18 PM
NCT ID:
NCT02377206
Eligibility Criteria:
Inclusion Criteria:
* Informed consent
* Age more than 50 years (included)
* necessary knowledge of French (write and oral) to do neuropsychological tests
* Study level upper (or equal) than 7 years (considering first year of grammar-school as start)
* People with Alzheimer Disease defined as National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) standards : Light to mild AD defined by Mini-Mental State Examination (MMSE) score between 15 and 25 (included)
* Social security affiliation.
Exclusion Criteria:
* MMSE score lower than 15 and upper or equal to 26
* Evolutive disease which could possibly had consequences on central nervous system
* Inflammatory disease or evolutive neoplasia and/or C reactive protein (CRP) upper than 10mg/L
* Chronic use of alchohol and/or drug
* Serious depression defined by Montgomery Asberg Depression Rating Scale (MADRS) score higher than 18
* Surgical or medical condition in the last 3 months
* Long term treatment which could possibly interfere with inflammatory process (especially the month before PET \[18F\]DPA-714 imaging).
* Treatment by N-Methyl-D-Aspartate antagonist
* Treatment by Minocycline
* Treatment by benzodiazepine (especially the month before PET \[18F\]DPA-714 imaging) (Zolpidem, zopiclone and loprazolam excepted)
* Anomaly at neurological examination which is not a classical symptom
* Contraindication to magnetic resonance imaging (RMI)
* Florbetapir\[18F\] hypersensibility
* Participation to an other experimental protocol with drug.
* people under guardianship
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
50 Years
Study:
NCT02377206
Study Brief:
Protocol Section:
NCT02377206